Cargando…

Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial

INTRODUCTION: A December 2019 WHO rapid communication recommended the use of 9-month all-oral regimens for treating multidrug-resistant tuberculosis (MDR-TB). Besides the clinical benefits, they are thought to be less costly than the injectable-containing regimens, for both the patient and the healt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosu, Laura, Madan, Jason, Worrall, Eve, Tomeny, Ewan, Squire, Bertel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Health Economics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754660/ https://www.ncbi.nlm.nih.gov/pubmed/33371043 http://dx.doi.org/10.1136/bmjopen-2020-042390

Ejemplares similares

Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol
por: Gama, Elvis, et al.
Publicado: (2016)

Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial
por: Madan, Jason J, et al.
Publicado: (2020)

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020)

Cost of digital technologies and family-observed DOT for a shorter MDR-TB regimen: a modelling study in Ethiopia, India and Uganda
por: Rosu, Laura, et al.
Publicado: (2023)

Effectiveness and safety of bedaquiline-based, modified all-oral 9–11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam
por: Nguyen, Thi Mai Phuong, et al.
Publicado: (2023)

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study
por: Ndjeka, Norbert, et al.
Publicado: (2022)

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin‐resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2022)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB
por: Lewis, Joseph M., et al.
Publicado: (2016)

Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam
por: Nguyen, Thi Mai Phuong, et al.
Publicado: (2022)

Modelling the impact of chest X-ray and alternative triage approaches prior to seeking a tuberculosis diagnosis
por: Shazzadur Rahman, Abu A. M., et al.
Publicado: (2019)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
por: Gao, Jing-Tao, et al.
Publicado: (2021)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
por: Hatami, Hossein, et al.
Publicado: (2022)

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial
por: Nunn, Andrew J, et al.
Publicado: (2014)

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
por: Goodall, Ruth L, et al.
Publicado: (2022)

Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China
por: Tong, Enyu, et al.
Publicado: (2023)

Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China
por: Agnarson, Abela Mpobela, et al.
Publicado: (2020)

Dataset on the in-stream and off-stream economic value of water
por: Lowe, Benjamin H., et al.
Publicado: (2020)

Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
por: Gomez, Gabriela Beatriz, et al.
Publicado: (2021)

Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis
por: Bouton, Tara C., et al.
Publicado: (2019)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

1884. Clinical Outcomes Among Patients with Drug-Resistant Tuberculosis Receiving Bedaquiline or Delamanid Containing Regimens
por: Kempker, Russell R, et al.
Publicado: (2019)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis
por: Tack, Ilse, et al.
Publicado: (2020)

Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
por: Phillips, P. P. J., et al.
Publicado: (2020)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

TB morbidity estimates overlook the contribution of post-TB disability: evidence from urban Malawi
por: Tomeny, Ewan M, et al.
Publicado: (2022)

Stakeholder perspectives around post-TB wellbeing and care in Kenya and Malawi
por: Karanja, Sarah, et al.
Publicado: (2022)

The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
por: Lin, Huang-Shen, et al.
Publicado: (2016)

Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis: insights from a qualitative study
por: Tu, Pham Hien Trang, et al.
Publicado: (2022)

Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
por: Wolfson, Lara J., et al.
Publicado: (2015)

India should speed up access to bedaquiline-based all-oral regimens, not procrastinate further
por: Udwadia, Zarir F, et al.
Publicado: (2021)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
por: Svensson, Elin M., et al.
Publicado: (2015)

Bacterial growth dynamics and pharmacokinetic–pharmacodynamic relationships of rifampicin and bedaquiline in BALB/c mice
por: Muliaditan, Morris, et al.
Publicado: (2021)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis
por: Yao, Ge, et al.
Publicado: (2023)

Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China
por: Zhang, Shao-Jun, et al.
Publicado: (2022)

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
por: Andries, Koen, et al.
Publicado: (2014)

Daily Dosing for Bedaquiline in Patients with Tuberculosis
por: Salinger, David H., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_op3ktal52mu1el78gqfdec45ao